Pfizer Q3 2026 earnings

PFE · 2026-11-03 08:07 BMO ET · 8-K on SEC

Revenue and EPS declined sequentially, with adjusted EBITDA margin expanding year-over-year despite lower sales.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$13.5B-3%-4%Ex. 99.1, income statement
EPS (GAAP)$0.22-19%-0.10Ex. 99.1, income statement
EPS (adjusted)$0.78+5%-0.02Ex. 99.1, income statement
Net income$2.0B-19%-0.8Ex. 99.1, income statement
Adj. EBITDA$3.8B+2%-0.2Ex. 99.1, income statement
Adj. EBITDA margin28.2%+1.2 pp-0.3 ppEx. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
Innovation$6.1B-4%45%Lower sales of Comirnaty and Xeljanz
Established Products$7.4B-2%55%Lower sales of Lyrica and Sutent

Margins and costs

  • Gross margin 79.2% (prior 79.5%, change -0.3 pp)
  • Operating expenses $9.7B (+3% YoY)
  • One-offs in the quarter Credit losses on loans: $0.2B; Other income (expense): $0.1B
  • Effective tax rate 20.0% (prior-year 20.0%, year-to-date 20.0%)
  • Non-GAAP bridge Adds back credit losses on loans and other income (expense) to arrive at adjusted results; these add-backs recur.

KPIs

MetricActualPrior quarterPrior yearChange
Free cash flow$2.5B$2.8B$2.6B-0.3
R&D expenses$2.6B$2.6B$2.7B-0.1
SG&A expenses$7.1B$7.0B$7.0B+0.1

Guidance

MetricGuidePrior guideChange
Revenue$13.8B - $14.2B$13.8B - $14.2BNo change
EPS (adjusted)$0.78 - $0.82$0.78 - $0.82No change
Adj. EBITDA margin28.0% - 28.5%28.0% - 28.5%No change

What drove it

  • Revenue story Innovation and Established Products both declined sequentially by 4% and 2%, respectively, driven by lower sales of Comirnaty, Xeljanz, Lyrica, and Sutent.
  • EPS story Adjusted EPS grew 5% year-over-year, supported by higher adjusted EBITDA, but declined sequentially due to lower revenue and a slight margin compression.
  • One-off check Credit losses on loans of $0.2B and other income (expense) of $0.1B are non-recurring items impacting GAAP results.

The good

  • Adjusted EBITDA margin expanded 1.2 pp year-over-year to 28.2%
  • Adjusted EPS grew 5% year-over-year

The bad

  • Revenue declined 4% sequentially and 3% year-over-year
  • Free cash flow declined 0.3 sequentially

The ugly

  • none

Open questions

  • The release does not quantify the impact of the lower sales of Comirnaty, Xeljanz, Lyrica, and Sutent on the sequential decline.
  • The release does not provide a breakdown of the $0.1B other income (expense) item.
Full release

Pfizer (PFE) earnings release, November 3, 2026

Pfizer Inc (PFE) · Form 8-K, Item 2.02 · Filed · SEC filing

Attachments

Seq Document Description

───────────────────────────────────────────────────────────────────────────────

2 pfe-9272026xex99.htm Additional exhibits

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Pfizer earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.